Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.

× No keyword cloud information.

18 in total

Review 1. Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy.

Authors: Lingjian Yang; Catharine Ml West
Journal: Br J Radiol Date: 2018-03-20 Impact factor: 3.039

Review 2. Targeting tumour hypoxia: shifting focus from oxygen supply to demand.

Authors: James T Coates; Michael Skwarski; Geoff S Higgins
Journal: Br J Radiol Date: 2018-02-19 Impact factor: 3.039

Review 3. [Target volume concepts in radiotherapy and their implications for imaging].

Authors: N G Burnet; D J Noble; A Paul; G A Whitfield; S Delorme
Journal: Radiologe Date: 2018-08 Impact factor: 0.635

Review 4. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

Authors: Holly E Barker; James T E Paget; Aadil A Khan; Kevin J Harrington
Journal: Nat Rev Cancer Date: 2015-07 Impact factor: 60.716

5. Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study.

Authors: C Paterson; S Allwood-Spiers; I McCrea; J Foster; M McJury; M Thomson; M Sankaralingam; D Grose; A James; M Rizwanullah; P McLoone; A Chalmers; A Duffton
Journal: Clin Transl Radiat Oncol Date: 2017-01-10

10. Revised Modelling of the Addition of Synchronous Chemotherapy to Radiotherapy in Squamous Cell Carcinoma of the Head and Neck-A Low α/β?

Authors: James Best; Charles Fong; Helen Benghiat; Hisham Mehanna; John Glaholm; Andrew Hartley
Journal: Medicines (Basel) Date: 2018-06-13

NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.

Review 1. Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy.

Review 2. Targeting tumour hypoxia: shifting focus from oxygen supply to demand.

Review 3. [Target volume concepts in radiotherapy and their implications for imaging].

Review 4. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

5. Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study.

Review 6. Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer.

Review 7. Hypoxia Signaling in Cancer: From Basics to Clinical Practice.

Review 8. Improving radiotherapy in cancer treatment: Promises and challenges.

9. Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer.

10. Revised Modelling of the Addition of Synchronous Chemotherapy to Radiotherapy in Squamous Cell Carcinoma of the Head and Neck-A Low α/β?